High-throughput virtual laboratory for drug discovery using massive datasets

被引:29
|
作者
Glaser, Jens [1 ]
Vermaas, Josh V. [1 ]
Rogers, David M. [1 ]
Larkin, Jeff [2 ]
LeGrand, Scott [2 ]
Boehm, Swen [3 ]
Baker, Matthew B. [3 ]
Scheinberg, Aaron [4 ]
Tillack, Andreas F. [5 ]
Thavappiragasam, Mathialakan [6 ]
Sedova, Ada [6 ]
Hernandez, Oscar [3 ]
机构
[1] Oak Ridge Natl Lab, Natl Ctr Computat Sci, Oak Ridge, TN 37831 USA
[2] NVIDIA Corp, Santa Clara, CA USA
[3] Oak Ridge Natl Lab, Comp Sci & Math Div, Oak Ridge, TN 37831 USA
[4] Jubilee Dev, Cambridge, MA USA
[5] Scripps Res, San Diego, CA USA
[6] Oak Ridge Natl Lab, Biosci Div, Oak Ridge, TN 37831 USA
关键词
High-throughput virtual screening; drug discovery; GPU acceleration; high-performance database query; MOLECULAR DOCKING; RATIONAL DESIGN; INHIBITORS; ACCURATE;
D O I
10.1177/10943420211001565
中图分类号
TP3 [计算技术、计算机技术];
学科分类号
0812 ;
摘要
Time-to-solution for structure-based screening of massive chemical databases for COVID-19 drug discovery has been decreased by an order of magnitude, and a virtual laboratory has been deployed at scale on up to 27,612 GPUs on the Summit supercomputer, allowing an average molecular docking of 19,028 compounds per second. Over one billion compounds were docked to two SARS-CoV-2 protein structures with full optimization of ligand position and 20 poses per docking, each in under 24 hours. GPU acceleration and high-throughput optimizations of the docking program produced 350x mean speedup over the CPU version (50x speedup per node). GPU acceleration of both feature calculation for machine-learning based scoring and distributed database queries reduced processing of the 2.4 TB output by orders of magnitude. The resulting 50x speedup for the full pipeline reduces an initial 43 day runtime to 21 hours per protein for providing high-scoring compounds to experimental collaborators for validation assays.
引用
收藏
页码:452 / 468
页数:17
相关论文
共 50 条
  • [41] High-Throughput Screening of Biodiversity for Antibiotic Discovery
    Terekhov, S. S.
    Osterman, I. A.
    Smirnov, I. V.
    ACTA NATURAE, 2018, 10 (03): : 23 - 29
  • [42] High-Throughput Screening for the Discovery of Enzyme Inhibitors
    Lloyd, Matthew D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 10742 - 10772
  • [43] High-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional models
    Martinez, Natalia J.
    Titus, Steven A.
    Wagner, Amanda K.
    Simeonov, Anton
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (12) : 1347 - 1361
  • [44] Pooling in high-throughput drug screening
    Kainkaryam, Raghunandan M.
    Woolf, Peter J.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (03) : 339 - 350
  • [45] Integration of Virtual and High Throughput Screening in Lead Discovery Settings
    Polgar, Timea
    Keseru, Gyoergy M.
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2011, 14 (10) : 889 - 897
  • [46] High throughput screening in drug discovery
    Carnero A.
    Clinical and Translational Oncology, 2006, 8 (7) : 482 - 490
  • [47] Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery
    Sally L. Hampton
    Anne I. Kinnaird
    Cell Biology and Toxicology, 2010, 26 : 43 - 55
  • [48] A solid-phase glycosyltransferase assay for high-throughput screening in drug discovery research
    Donovan, RS
    Datti, A
    Baek, MG
    Wu, QQ
    Sas, IJ
    Korczak, B
    Berger, EG
    Roy, R
    Dennis, JW
    GLYCOCONJUGATE JOURNAL, 1999, 16 (10) : 607 - 615
  • [49] Comprehensive Survey of Consensus Docking for High-Throughput Virtual Screening
    Blanes-Mira, Clara
    Fernandez-Aguado, Pilar
    De Andres-Lopez, Jorge
    Fernandez-Carvajal, Asia
    Ferrer-Montiel, Antonio
    Fernandez-Ballester, Gregorio
    MOLECULES, 2023, 28 (01):
  • [50] Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery
    Hampton, Sally L.
    Kinnaird, Anne I.
    CELL BIOLOGY AND TOXICOLOGY, 2010, 26 (01) : 43 - 55